BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 28193998)

  • 1. Inhibition of serotonin receptor type 1 in acute myeloid leukemia impairs leukemia stem cell functionality: a promising novel therapeutic target.
    Etxabe A; Lara-Castillo MC; Cornet-Masana JM; Banús-Mulet A; Nomdedeu M; Torrente MA; Pratcorona M; Díaz-Beyá M; Esteve J; Risueño RM
    Leukemia; 2017 Nov; 31(11):2288-2302. PubMed ID: 28193998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
    Al-Mawali A; Gillis D; Lewis I
    J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors.
    Venton G; Pérez-Alea M; Baier C; Fournet G; Quash G; Labiad Y; Martin G; Sanderson F; Poullin P; Suchon P; Farnault L; Nguyen C; Brunet C; Ceylan I; Costello RT
    Blood Cancer J; 2016 Sep; 6(9):e469. PubMed ID: 27611922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute Myeloid Leukemia Stem Cell Heterogeneity and Its Clinical Relevance.
    Karantanos T; Jones RJ
    Adv Exp Med Biol; 2019; 1139():153-169. PubMed ID: 31134500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.
    Iwasaki M; Liedtke M; Gentles AJ; Cleary ML
    Cell Stem Cell; 2015 Oct; 17(4):412-21. PubMed ID: 26387756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
    Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
    Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
    Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
    Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TWIST-1 promotes cell growth, drug resistance and progenitor clonogenic capacities in myeloid leukemia and is a novel poor prognostic factor in acute myeloid leukemia.
    Wang N; Guo D; Zhao YY; Dong CY; Liu XY; Yang BX; Wang SW; Wang L; Liu QG; Ren Q; Lin YM; Ma XT
    Oncotarget; 2015 Aug; 6(25):20977-92. PubMed ID: 26023795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukemia stem cells.
    Buss EC; Ho AD
    Int J Cancer; 2011 Nov; 129(10):2328-36. PubMed ID: 21796620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo.
    Saito Y; Yuki H; Kuratani M; Hashizume Y; Takagi S; Honma T; Tanaka A; Shirouzu M; Mikuni J; Handa N; Ogahara I; Sone A; Najima Y; Tomabechi Y; Wakiyama M; Uchida N; Tomizawa-Murasawa M; Kaneko A; Tanaka S; Suzuki N; Kajita H; Aoki Y; Ohara O; Shultz LD; Fukami T; Goto T; Taniguchi S; Yokoyama S; Ishikawa F
    Sci Transl Med; 2013 Apr; 5(181):181ra52. PubMed ID: 23596204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
    Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
    Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
    Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
    Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression.
    Kikushige Y; Miyamoto T; Yuda J; Jabbarzadeh-Tabrizi S; Shima T; Takayanagi S; Niiro H; Yurino A; Miyawaki K; Takenaka K; Iwasaki H; Akashi K
    Cell Stem Cell; 2015 Sep; 17(3):341-52. PubMed ID: 26279267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation.
    Qi J; Singh S; Hua WK; Cai Q; Chao SW; Li L; Liu H; Ho Y; McDonald T; Lin A; Marcucci G; Bhatia R; Huang WJ; Chang CI; Kuo YH
    Cell Stem Cell; 2015 Nov; 17(5):597-610. PubMed ID: 26387755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repositioning of bromocriptine for treatment of acute myeloid leukemia.
    Lara-Castillo MC; Cornet-Masana JM; Etxabe A; Banús-Mulet A; Torrente MÁ; Nomdedeu M; Díaz-Beyá M; Esteve J; Risueño RM
    J Transl Med; 2016 Sep; 14(1):261. PubMed ID: 27604463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia.
    Laverdière I; Boileau M; Neumann AL; Frison H; Mitchell A; Ng SWK; Wang JCY; Minden MD; Eppert K
    Blood Cancer J; 2018 Jun; 8(6):52. PubMed ID: 29921955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML.
    Banús-Mulet A; Etxabe A; Cornet-Masana JM; Torrente MÁ; Lara-Castillo MC; Palomo L; Nomdedeu M; Díaz-Beyá M; Solé F; Nomdedeu B; Esteve J; Risueño RM
    Sci Rep; 2018 Sep; 8(1):13883. PubMed ID: 30224768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of acute myelogenous leukemia stem cell properties after treatment and progression.
    Ho TC; LaMere M; Stevens BM; Ashton JM; Myers JR; O'Dwyer KM; Liesveld JL; Mendler JH; Guzman M; Morrissette JD; Zhao J; Wang ES; Wetzler M; Jordan CT; Becker MW
    Blood; 2016 Sep; 128(13):1671-8. PubMed ID: 27421961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progress in the studies of acute myelogenous leukemia stem cell].
    Cui JW; Zhang XM; Wang GJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Oct; 11(5):549-52. PubMed ID: 14575558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.